Medical research company Recardio has halted clinical trials of its heart drug in the UK , citing concerns over Brexit . Clinical trials of a new heart drug have been stopped in the UK because of concerns over Brexit. The US company was due to conduct trials of dutogliptin on patients in Clydebank , Exeter and Leeds , but has now ceased all its activities in the UK . Recardio cited a " significant risk " from Brexit and " unresolved " issues with the European Defence Agency , the company reportedly wrote in an email to its research team . The position may change once the post - Brexit regulatory situation is clearer , it added .
Medical research company Recardio has halted clinical trials of its heart drug in the UK , citing concerns over Brexit . The US company was due to conduct trials of dutogliptin on patients in Clydebank , Exeter and Leeds , but has now ceased all its activities in the UK . Recardio cited a " significant risk " from Brexit and " unresolved " issues with the European Defence Agency , the company reportedly wrote in an email to its research team . The position may change once the post - Brexit regulatory situation is clearer , it added .